Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model.

Overexpression of vascular endothelial growth factor (VEGF) is implicated in the development of vascular leakage and retinal neovascularization in diabetic subjects. The objective of this study was to determine whether celecoxib, a selective cyclooxygenase-2 enzyme inhibitor, reaches ocular tissues following oral administration and inhibits the retinal VEGF expression and vascular leakage in a streptozotocin-induced diabetic rat model. After administering a single intraperitoneal injection of streptozotocin (60 mg/kg) to Sprague-Dawley rats and ensuring the induction of diabetes at the end of 24 h, celecoxib was administered b.i.d. by oral gavage (50 mg/kg). On day 8, the animals were sacrificed and the retinal VEGF and cyclooxygenase-2 mRNA levels, ocular tissue celecoxib concentrations, and the vitreous/plasma protein ratio were determined. In diabetic rats, the retinal VEGF mRNA expression was 2.3-fold compared to controls, with a corresponding increase in cyclooxygenase-2 mRNA expression. Celecoxib treatment inhibited VEGF mRNA expression without any significant reduction in cyclooxygenase-2 mRNA. Furthermore, the retinal vascular leakage estimated as vitreous to plasma protein ratio increased in diabetic animals from 0.35+/-0.1 to 1.1+/-0.1 and celecoxib treatment significantly decreased this ratio to 0.4+/-0.1. Celecoxib levels were 24.8+/-6.6, 1.9+/-1, 1.7+/-0.8, and 6.9+/-0.9 ng/mg in the retina, vitreous, lens, and cornea, respectively. The plasma celecoxib levels were 85+/-24 ng/ml. Thus, celecoxib reaches the retina after oral administration and reduces diabetes-induced retinal VEGF mRNA expression and vascular leakage by inhibiting the activity of cyclooxygenase-2 enzyme.

[1]  S. Vinores.  Assessment of blood-retinal barrier integrity. , 1995, Histology and histopathology.

[2]  A. Garner.  Histopathology of diabetic retinopathy in man , 1993, Eye.

[3]  D. Foreman,et al.  VEGF localisation in diabetic retinopathy , 1998, The British journal of ophthalmology.

[4]  J. Gierse,et al.  Kinetic basis for selective inhibition of cyclo-oxygenases. , 1999, The Biochemical journal.

[5]  D. Nie,et al.  Thromboxane A2 Regulation of Endothelial Cell Migration, Angiogenesis, and Tumor Metastasis☆ , 2000 .

[6]  D. Heijde.  The continuing challenge of predictive factors in rheumatoid arthritis: prediction or association? , 1997 .

[7]  Elizabeth M. Topp,et al.  Transport processes in pharmaceutical systems , 1999 .

[8]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[9]  E. Voest,et al.  Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. , 1996, The Journal of clinical investigation.

[10]  A. Adamis,et al.  Is diabetic retinopathy an inflammatory disease? , 2002, The British journal of ophthalmology.

[11]  J. Pulido,et al.  Protein levels in the vitreous of rats with streptozotocin-induced diabetes mellitus , 1993, Brain Research Bulletin.

[12]  A. Jawerbaum,et al.  Evolution of streptozotocin-pancreatic damage in the rat: modulatory effect of endothelins on the nitridergic and prostanoid pathway. , 1999, Nitric oxide : biology and chemistry.

[13]  Y. Okuda,et al.  Effects of high glucose concentration and a thromboxane synthase inhibitor on the production of thromboxane A2 and prostaglandin I2 and E2 by retinal endothelial cells. , 1995, Life sciences.

[14]  M. Chin,et al.  Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. , 2001, Investigative ophthalmology & visual science.

[15]  T. Warner,et al.  Ex vivo assay to determine the cyclooxygenase selectivity of non‐steroidal anti‐inflammatory drugs , 1999, British journal of pharmacology.

[16]  M. Pourcyrous,et al.  Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells. , 2001, American journal of physiology. Cell physiology.

[17]  C. Glass,et al.  Cyclopentenone prostaglandins: New insights on biological activities and cellular targets , 2001, Medicinal research reviews.

[18]  R. Robertson,et al.  Basal expression of cyclooxygenase-2 and nuclear factor-interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  L. Aiello,et al.  Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. , 1997, Diabetes/metabolism reviews.

[20]  U. Pagotto,et al.  Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells. , 1999, The Journal of endocrinology.

[21]  Bernd Kirchhof,et al.  Nonsteroidal anti‐inflammatory drugs prevent early diabetic retinopathy via TNF‐α suppression , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  J. Morrow,et al.  A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. , 1997, Gastroenterology.

[23]  U. Kompella,et al.  Induction of vascular endothelial growth factor by 4-hydroxynonenal and its prevention by glutathione precursors in retinal pigment epithelial cells. , 2002, European journal of pharmacology.

[24]  J Y Zhang,et al.  Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[25]  D. Bouchier-Hayes,et al.  Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells , 2001, British Journal of Cancer.

[26]  U. Kompella,et al.  Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. , 2001, European journal of pharmacology.

[27]  Susanna Wu-Pong,et al.  Biopharmaceutical Drug Design and Development , 1999, Humana Press.

[28]  M. Lavail,et al.  Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells. , 1998, Investigative ophthalmology & visual science.

[29]  L. Aiello,et al.  Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  N. Ferrara,et al.  Vascular endothelial growth factor and the regulation of angiogenesis. , 2000, Recent progress in hormone research.

[31]  L. Aiello,et al.  Retinal expression, regulation, and functional bioactivity of prostacyclin-stimulating factor. , 2000, The Journal of clinical investigation.

[32]  K. Eakins,et al.  Prostaglandin and non-prostaglandin mediated breeakdown of the blood-aqueous barrier. , 1977, Experimental eye research.

[33]  U. Kompella.  Protein Drug Delivery , 1999 .

[34]  J. Cunha-Vaz,et al.  Effect of cyclosporin-A on the blood--retinal barrier permeability in streptozotocin-induced diabetes. , 2000, Mediators of inflammation.

[35]  P. Isakson,et al.  The discovery and function of COX-2. , 1997, The Journal of rheumatology. Supplement.

[36]  R. A. Field,et al.  Studies on Salicylates and Complement in Diabetes , 1966, Diabetes.

[37]  F. Blodi.  Pathobiology of Ocular Disease , 1983 .

[38]  H. Suzuki,et al.  Effects of intraocular or systemic administration of neutralizing antibody against vascular endothelial growth factor on the murine experimental model of retinopathy. , 1999, Life sciences.

[39]  U. Kompella,et al.  A Biodegradable Injectable Implant Sustains Systemic and Ocular Delivery of an Aldose Reductase Inhibitor and Ameliorates Biochemical Changes in a Galactose-Fed Rat Model for Diabetic Complications , 2002, Pharmaceutical Research.

[40]  Joan W. Miller,et al.  Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. , 1994, American journal of ophthalmology.

[41]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[42]  C. Fang,et al.  Expression of constitutive cyclo-oxygenase (COX-1) in rats with streptozotocin-induced diabetes; effects of treatment with evening primrose oil or an aldose reductase inhibitor on COX-1 mRNA levels. , 1997, Prostaglandins, leukotrienes, and essential fatty acids.

[43]  Marjorie Dunlop,et al.  Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature. , 1999, Current eye research.

[44]  Y. Kotake,et al.  COX-2 inhibition prevents insulin-dependent diabetes in low-dose streptozotocin-treated mice. , 2000, Biochemical and biophysical research communications.

[45]  R. S. Rogers,et al.  Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.

[46]  R. DuBois,et al.  Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. , 2000, Gastroenterology.

[47]  F. Silverstein,et al.  Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor , 2000, American Journal of Gastroenterology.

[48]  G. Yancopoulos,et al.  VEGF-initiated blood-retinal barrier breakdown in early diabetes. , 2001, Investigative ophthalmology & visual science.

[49]  B. Varnum,et al.  TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. , 1991, The Journal of biological chemistry.

[50]  T. Kern,et al.  Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. , 2001, Diabetes.

[51]  J. D. Salvo,et al.  Human Retinal Vascular Cells Differ from Umbilical Cells in Synthetic Functions and Their Response to Glucose , 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[52]  M J Dunn,et al.  Cyclooxygenase-2 Expression Inhibits Trophic Withdrawal Apoptosis in Nerve Growth Factor-differentiated PC12 Cells* , 2000, The Journal of Biological Chemistry.

[53]  J. Morrow,et al.  Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. , 1998, Cancer research.

[54]  P. Campochiaro,et al.  Intravitreal Sustained Release of VEGF Causes Retinal Neovascularization in Rabbits and Breakdown of the Blood– Retinal Barrier in Rabbits and Primates , 1997 .

[55]  L. Aiello,et al.  Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Masferrer,et al.  Celecoxib: a specific COX-2 inhibitor with anticancer properties. , 2002, Cancer control : journal of the Moffitt Cancer Center.